IUL.F IMMUCELL CORP. DL-10

Healthcare Biotechnology Frankfurt Exchange
9.05 EUR
Close of Nov 12, 2026
3.88 10.20
Market cap
EUR 82.2M
P/E
150.8x
P/B
3.04x
ROE
24.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is IUL.F undervalued?

Graham number

The Graham number of IMMUCELL CORP. DL-10 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IMMUCELL CORP. DL-10 fundamental analysis

No fundamental analysis for IMMUCELL CORP. DL-10 yet.

IMMUCELL CORP. DL-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IMMUCELL CORP. DL-10

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment o…

Full company profile